Skip to content
2000
Volume 20, Issue 3
  • ISSN: 2772-4344
  • E-ISSN: 2772-4352

Abstract

Onychomycosis is regarded as one of the most common and least concerned fungal problems. Although various treatment approaches have been well-established, still treatment strategies suffer from certain drawbacks, so there is a need to discuss novel therapies that could ultimately eliminate all the conventional barriers. It is a nail infection that begins in the toenail and spreads, causing significant negative impacts on patients' quality of life. The purpose of this work was to highlight the limitations of conventional treatments and shed light on novel therapies for managing onychomycosis. A comprehensive review on existing topical and systemic therapies was conducted, with a focus on their drawbacks, such as recurrence and lower efficacy. This review aimed to explore the increasing prevalence of onychomycosis, which poses a serious health issue; however, the advent of nano-based drug delivery systems offers hope for more effective management of this prevalent disease. These systems could potentially overcome the limitations of conventional treatments, thereby improving patient outcomes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344335834250112164400
2025-01-31
2025-12-06

  • From This Site

    /content/journals/raaidd/10.2174/0127724344335834250112164400
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AL-Khikani FHO, Ayit AS. Major challenges in dermatophytosis treatment.Egypt J Dermatol Venereol20214111910.4103/ejdv.ejdv_23_20
     [Google Scholar]
  2. BodmanM.A. KrishnamurthyK. Onychomycosis. StatPearls.StatPearls Publishing2022
     [Google Scholar]
  3. ElewskiB.E. Onychomycosis: Pathogenesis, diagnosis, and management.Clin. Microbiol. Rev.199811341542910.1128/CMR.11.3.415 9665975
     [Google Scholar]
  4. AbdullahL. AbbasO. Common nail changes and disorders in older people: Diagnosis and management.Can. Fam. Physician2011572173181 21321168
     [Google Scholar]
  5. CohenJ.L. ScherR.K. PappertA.S. The nail and fungus infections.Cutaneous Fungal Infections1992106122
     [Google Scholar]
  6. AggarwalR. TarghotraM. KumarB. SahooP.K. ChauhanM.K. Treatment and management strategies of onychomycosis.J. Mycol. Med.202030210094910.1016/j.mycmed.2020.100949 32234349
     [Google Scholar]
  7. KotwalS SumbaliG ChauhanM Prevalence of onychomycosis among diabetic population of District Doda (UT of J&K, India) – a five-year survey. Arch Clin Med Microbiol20243311010.33140/ACMM.03.03.01
     [Google Scholar]
  8. TakeharaK. OeM. TsunemiY. Factors associated with presence and severity of toenail onychomycosis in patients with diabetes: A cross-sectional study.Int. J. Nurs. Stud.20114891101110810.1016/j.ijnurstu.2011.02.005 21367414
     [Google Scholar]
  9. GuptaA.K. MaysR.R. The impact of onychomycosis on quality of life: A systematic review of the available literature.Skin Appendage Disord.20184420821610.1159/000485632 30410887
     [Google Scholar]
  10. AngeloT. Borgheti-CardosoL.N. GelfusoG.M. TaveiraS.F. GratieriT. Chemical and physical strategies in onychomycosis topical treatment: A review.Med. Mycol.2016555myw08410.1093/mmy/myw084 27703019
     [Google Scholar]
  11. Maskan BermudezN. Rodríguez-TamezG. PerezS. TostiA. Onychomycosis: Old and new.J. Fungi20239555910.3390/jof9050559 37233270
     [Google Scholar]
  12. DiasM.F.R.G. Quaresma-SantosM.V.P. Bernardes-FilhoF. AmorimA.G.F. SchechtmanR.C. AzulayD.R. Update on therapy for superficial mycoses: Review article part I.An. Bras. Dermatol.201388576477410.1590/abd1806‑4841.20131996 24173183
     [Google Scholar]
  13. ZaneLT ChandaS CoronadoD Del RossoJ Antifungal agents for onychomycosis: New treatment strategies to improve safety.Dermatol Online J201622313030/qt8dg124gs10.5070/D3223030383 27136621
     [Google Scholar]
  14. DhamoonR.K. PopliH. GuptaM. Novel drug delivery strategies for the treatment of onychomycosis.Pharm. Nanotechnol.201971243810.2174/2211738507666190228104031 31092174
     [Google Scholar]
  15. HayR.J. BaranR. Onychomycosis: A proposed revision of the clinical classification.J. Am. Acad. Dermatol.20116561219122710.1016/j.jaad.2010.09.730 21501889
     [Google Scholar]
  16. ThomasJ. JacobsonG.A. NarkowiczC.K. PetersonG.M. BurnetH. SharpeC. Toenail onychomycosis: An important global disease burden.J. Clin. Pharm. Ther.201035549751910.1111/j.1365‑2710.2009.01107.x 20831675
     [Google Scholar]
  17. GhannoumM. MukherjeeP. IshamN. MarkinsonB. RossoJ.D. LealL. Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis.Int. J. Dermatol.201857213113810.1111/ijd.13690 28653769
     [Google Scholar]
  18. GuptaA.K. MaysR.R. VersteegS.G. ShearN.H. PiguetV. Update on current approaches to diagnosis and treatment of onychomycosis.Expert Rev. Anti Infect. Ther.2018161292993810.1080/14787210.2018.1544891 30411650
     [Google Scholar]
  19. SingalA. KayarkatteM.N. PandhiD. DasS. SharmaS. Nail dermoscopy (onychoscopy) findings in the diagnosis of primary onychomycosis: A cross-sectional study.Indian J. Dermatol. Venereol. Leprol.202086434134910.4103/ijdvl.IJDVL_100_19 32415047
     [Google Scholar]
  20. HanS.S. ParkG.H. LimW. Deep neural networks show an equivalent and often superior performance to dermatologists in onychomycosis diagnosis: Automatic construction of onychomycosis datasets by region-based convolutional deep neural network.PLoS One2018131e019149310.1371/journal.pone.0191493 29352285
     [Google Scholar]
  21. GroverC. KhuranaA. Onychomycosis: Newer insights in pathogenesis and diagnosis.Indian J. Dermatol. Venereol. Leprol.201278326327010.4103/0378‑6323.95440 22565425
     [Google Scholar]
  22. VenturaA. MazzeoM. GazianoR. GalluzzoM. BianchiL. CampioneE. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.Drug Des. Devel. Ther.2017112527253510.2147/DDDT.S136986
     [Google Scholar]
  23. BodmanM.A. KrishnamurthyK. Onychomycosis.In: StatPearls.Treasure Island, (FL)StatPearls Publishing2023
     [Google Scholar]
  24. PiracciniB. AlessandriniA. Onychomycosis: A review.J. Fungi201511304310.3390/jof1010030 29376897
     [Google Scholar]
  25. LeeD.K. LipnerS.R. Optimal diagnosis and management of common nail disorders.Ann. Med.202254169471210.1080/07853890.2022.2044511 35238267
     [Google Scholar]
  26. YamaguchiH. Potential of ravuconazole and its prodrugs as the new oraltherapeutics for onychomycosis.Med. Mycol. J.2016574E93E11010.3314/mmj.16‑00006 27904057
     [Google Scholar]
  27. KhannaD. BhartiS. Luliconazole for the treatment of fungal infections: An evidence-based review.Core Evid.2014911312410.2147/CE.S49629 25285056
     [Google Scholar]
  28. FinchJ.J. JinnaS. Spotlight on tavaborole for the treatment of onychomycosis.Drug Des. Devel. Ther.201596185619010.2147/DDDT.S81944 26640371
     [Google Scholar]
  29. VeigaF.F. CostaM.I. CóticaÉ.S.K. SvidzinskiT.I.E. NegriM. Propolis for the treatment of onychomycosis.Indian J. Dermatol.201863651551710.4103/ijd.IJD_365_17 30504984
     [Google Scholar]
  30. ElewskiB.E. RichP. PollakR. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.J. Am. Acad. Dermatol.201368460060810.1016/j.jaad.2012.10.013 23177180
     [Google Scholar]
  31. AkhtarN. SharmaH. PathakK. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals.Scientifica2016201611210.1155/2016/1387936 27123362
     [Google Scholar]
  32. VanstoneS. StoneJ.M. GordeevS.N. GuyR.H. Mechanism of human nail poration by high-repetition-rate, femtosecond laser ablation.Drug Deliv. Transl. Res.20199595696710.1007/s13346‑019‑00638‑x 31016477
     [Google Scholar]
  33. GuptaA.K. StecN. Recent advances in therapies for onychomycosis and its management.F1000 Res.2019896810.12688/f1000research.18646.1 31297182
     [Google Scholar]
  34. PollardT.D. BonettiM. DayA. Printing drugs onto nails for effective treatment of onychomycosis.Pharmaceutics202214244810.3390/pharmaceutics14020448 35214182
     [Google Scholar]
  35. AggarwalR. TarghotraM. SahooP.K. ChauhanM.K. Onychomycosis: Novel strategies for treatment.J. Drug Deliv. Sci. Technol.20205710177410.1016/j.jddst.2020.101774
     [Google Scholar]
  36. KesharwaniP. FatimaM. SinghV. Itraconazole and difluorinated-curcumin containing chitosan nanoparticle loaded hydrogel for amelioration of onychomycosis.Biomimetics20227420610.3390/biomimetics7040206 36412734
     [Google Scholar]
  37. BseisoE.A. NasrM. SammourO.A. Abd El GawadN.A. Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis.Drug Deliv.20162382813281910.3109/10717544.2015.1099059 26447337
     [Google Scholar]
  38. DantasK.N.M. AndradeL.R. LisboaE. Antimycotic nail polish based on humic acid‐coated silver nanoparticles for onychomycosis.J. Chem. Technol. Biotechnol.20219682208221810.1002/jctb.6676
     [Google Scholar]
  39. FloresF.C. ChiuW.S. BeckR.C.R. da SilvaC.B. Delgado-CharroM.B. Enhancement of tioconazole ungual delivery: Combining nanocapsule formulation and nail poration approaches.Int. J. Pharm.20185351-223724410.1016/j.ijpharm.2017.11.008 29126904
     [Google Scholar]
  40. AgrawalV. PatelR. PatelM. Design, characterization, and evaluation of efinaconazole loaded poly(D, L-lactide-co-glycolide) nanocapsules for targeted treatment of onychomycosis.J. Drug Deliv. Sci. Technol.20238010415710.1016/j.jddst.2023.104157
     [Google Scholar]
  41. GaballahE.Y. BorgT.M. MohamedE.A. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.Drug Deliv.20222913304331610.1080/10717544.2022.2144543 36372978
     [Google Scholar]
  42. KamalR. AwasthiA. PaulP. MirM.S. SinghS.K. DuaK. Novel drug delivery systems in colorectal cancer: Advances and future prospects.Pathol. Res. Pract.202426215554610.1016/j.prp.2024.155546 39191194
     [Google Scholar]
  43. MahtabA. AnwarM. MallickN. NazZ. JainG.K. AhmadF.J. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis.AAPS PharmSciTech20161761477149010.1208/s12249‑016‑0488‑0 26857516
     [Google Scholar]
  44. LavateS. ChaudhariS. Formulation and evaluation of voriconazole loaded nanoemulgel for the treatment of onychomycosis.Preprints202310.21203/rs.3.rs‑3156838/v1
     [Google Scholar]
  45. AbobakrF.E. FayezS.M. ElwazzanV.S. SakranW. Effect of different nail penetration enhancers in solid lipid nanoparticles containing terbinafine hydrochloride for treatment of onychomycosis.AAPS PharmSciTech20212213310.1208/s12249‑020‑01893‑9 33404930
     [Google Scholar]
  46. DudhipalaN. AyA.A. Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections.Chem. Phys. Lipids202023210495310.1016/j.chemphyslip.2020.104953 32814084
     [Google Scholar]
  47. Tuncay TanrıverdiS. Hilmioğlu PolatS. Yeşim MetinD. KandiloğluG. ÖzerÖ. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: In vitro and in vivo evaluation.J. Liposome Res.201626216317310.3109/08982104.2015.1067892 26226352
     [Google Scholar]
  48. ChouhanS.S. FarooquiN. MishraD.K. Formulation and evaluation of liposomal loaded nail lacquer containing luliconazole an antifungal drug.Asian J. Pharm. Pharmacol.20217313113710.31024/ajpp.2021.7.3.4
     [Google Scholar]
  49. GuptaI. AdinS.N. RashidM.A. AlhamhoomY. AqilM. MujeebM. Linalool-incorporated synergistically engineered modified liposomal nanocarriers for enhanced transungual delivery of terbinafine against onychomycosis.Materials20231612442410.3390/ma16124424 37374607
     [Google Scholar]
  50. FiroozA. ZamaniS. GhadreiA. Evaluation of efficacy and safety of topical nanoliposomal amphotericin B 0.4% gel as a potential treatment for onychomycosis: An interventional pilot clinical study.Dermatol. Ther.202320231995512410.1155/2023/9955124
     [Google Scholar]
/content/journals/raaidd/10.2174/0127724344335834250112164400
Loading
Novel Therapeutic Approaches Emerging in the Field of Onychomycosis
Recent Adv Antiinfect Drug Discov 20, 157 (2025); https://doi.org/10.2174/0127724344335834250112164400
/content/journals/raaidd/10.2174/0127724344335834250112164400
/content/journals/raaidd/10.2174/0127724344335834250112164400
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): mycoses; nanocarrier; onychocryptosis; Onychomycosis; superficial onychomycosis; total dystrophic onychomycosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test